文献速递乳腺癌放疗姑息放疗与转移瘤中枢神经肿瘤放疗

澳大利亚放射肿瘤学实践是否在明智选择:一项基于人群的研究发现

Are We Choosing Wisely in Radiation Oncology Practice-Findings From an Australian Population-Based Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2019-04-12

该研究评估了澳大利亚与新西兰放射肿瘤学院明智选择(CW)建议发布前后在维多利亚州放射治疗中的采纳情况。结果显示,2013至2017年间,早期乳腺癌大分割放疗使用率从42%升至82%,长疗程姑息性骨放疗从10%降至5%,立体定向脑放疗后辅助全脑放疗从4%降至0.7%,均与CW建议一致。作者认为部分建议需修订以反映快速发展的证据。

要点

  • 早期乳腺癌大分割放疗使用率从2013年42%升至2017年82%(P < .001)。
  • 姑息性骨放疗中长疗程(>10次)比例从2013年10%降至2017年5%(P < .001)。
  • 脑转移立体定向放疗后1个月内辅助全脑放疗比例从2013年4%降至2017年0.7%(P = .02)。

核心结论

  • 2013至2017年间澳大利亚放射肿瘤学实践发生显著变化,与明智选择建议一致。
  • 部分明智选择建议需修订以反映放射肿瘤学快速发展的证据。

研究设计与样本

  • 研究基于澳大利亚维多利亚州放疗最小数据集,纳入与5条明智选择建议中3条相关的三组患者。
  • 早期乳腺癌组为年龄≥50岁、接受乳腺放疗(除外淋巴结照射)的女性,共8204例。
  • 姑息性骨放疗组为接受姑息性骨放疗的癌症患者(除外原发性骨恶性肿瘤),共15634疗程。
  • 立体定向脑放疗组为接受脑立体定向放疗的癌症患者(除外中枢神经系统原发恶性肿瘤),共1049例。
  • 采用Cochrane-Armitage检验评估实践随时间的变化。

主要发现

  • 8204例乳腺放疗患者中,大分割放疗(<25次)使用率从2013年42%升至2017年82%(P < .001),且各机构均呈逐步上升。
  • 15634疗程姑息性骨放疗中,仅1279疗程(8%)为>10次,该比例从2013年10%降至2017年5%(P < .001)。
  • 1049例脑转移立体定向放疗患者中,仅2%接受辅助全脑放疗,该比例从2013年4%降至2017年0.7%(P = .02)。

关键数值与推荐

  • 明智选择建议相关结局包括:乳腺癌大分割放疗(<25次)使用、姑息性骨放疗长疗程(>10次)使用、立体定向放疗后1个月内辅助全脑放疗使用。
  • 早期乳腺癌大分割放疗使用率2013年42% vs 2017年82%(P < .001)。
  • 姑息性骨放疗>10次比例2013年10% vs 2017年5%(P < .001)。
  • 立体定向放疗后辅助全脑放疗比例2013年4% vs 2017年0.7%(P = .02)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the adoption of the Royal Australian and New Zealand College of Radiologists Choosing Wisely (CW) radiation oncology recommendations before and after the release of the recommendations. METHODS AND MATERIALS: The Victorian Radiotherapy Minimum Data Set captures details of radiation therapy delivered in the state of Victoria, Australia. This study included the following 3 groups of patients relevant to 3 of the 5 CW recommendations: women who received a diagnosis of early-stage breast cancer at age ≥50 years who had breast radiation therapy (excluding nodal irradiation), patients with cancer who had palliative bone radiation therapy (excluding those with primary bone malignancies), and patients with cancer who had stereotactic radiation therapy to the brain (excluding those with primary malignancies of the central nervous system). The outcomes of interest were use of hypofractionated breast radiation therapy (<25 fractions), use of long-course palliative bone radiation therapy (>10 fractions), and use of adjuvant whole brain radiation therapy within 1 month of stereotactic radiation therapy. The Cochrane-Armitage test was used to evaluate changes in practice over time. RESULTS: Among the 8204 patients who had breast radiation therapy, there was an increase in hypofractionation use from 42% in 2013 to 82% in 2017 (P < .001). The progressive increase in hypofractionation use was observed across institutions. Of the 15,634 courses of palliative bone radiation therapy delivered, only 1279 (8%) were >10 fractions, and this decreased from 10% in 2013 to 5% in 2017 (P < .001). Of the 1049 patients who received stereotactic radiation therapy for brain metastases, only 2% had adjuvant whole brain radiation therapy, and this decreased from 4% in 2013 to 0.7% in 2017 (P = .02). CONCLUSIONS: There was a significant change in radiation oncology practice in Australia between 2013 and 2017, in line with the CW recommendations. However, some of the recommendations need to be revised to reflect the rapidly evolving evidence in radiation oncology.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Ong WL, Foroudi F, Milne RL, et al. Are We Choosing Wisely in Radiation Oncology Practice-Findings From an Australian Population-Based Study. Int J Radiat Oncol Biol Phys. 2019. PMID: 30981834. doi:10.1016/j.ijrobp.2019.03.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。